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Background and aims: We studied whether low pre-treatment muscle mass, measured with 40 
CT at thoracic (T4) or lumbar level (L3) associates with early termination of chemotherapy 41 
related to toxicity in head and neck cancer (HNC) patients. 42 
Methods: This was a retrospective chart and image review. Adult HNC patients treated with 43 
(surgery and) platinum-based chemo-radiotherapy were included if a pre-treatment CT scan at 44 
T4 or L3 level was available. Muscle mass was evaluated by assessment of skeletal muscle 45 
index (SMI; cm2/m2). T4 and L3 SMI measurements were corrected for deviation from their 46 
respective means and were merged into one score for SMI difference (cm2/m2). All cases were 47 
assessed for presence of toxicity-related unplanned early termination of chemotherapy (‘early 48 
termination’). Univariate and multivariate logistic regression models were used to investigate 49 
associations between pooled SMI and early termination.  50 
Results: 213 patients (age: 57.9±10.3 y, male: 77%, T4 image: 45%) were included. A 51 
significant association between SMI as a continuous variable and early termination was 52 
found, both in the univariate analysis (p=0.007, OR=0.96 [0.94-0.99]) and the multivariate 53 
analysis (p=0.021, OR 0.96 [0.92-0.99]). The multivariate models identified potential 54 
associations with type of chemotherapy, presence of co-morbidity, a combination of (former) 55 
smoking and alcohol consumption, and sex. 56 
Conclusion: Lower muscle mass was robustly associated with higher odds of early 57 
termination of chemotherapy in HNC patients. Further prospective studies are required to 58 
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Decreased oral intake due to tumor location cancer treatment, and/or cachexia is common in 87 
patients with head and neck cancer (HNC) and may induce loss of skeletal muscle [1-4]. In 88 
turn, low muscle mass has a negative impact on overall function and survival in patients with 89 
HNC [5-9]. However, the treatment approach in patients with locally advanced HNC can be 90 
aggressive and may consist of surgery followed by radiotherapy, with or without concomitant 91 
chemotherapy. In patients not eligible for surgery or when the anticipated functional outcome 92 
with surgery is poor, radiotherapy with concomitant chemotherapy is preferred [10-12]. 93 
Although prognosis improves when patients are capable of completing their therapy, early 94 
termination of treatment related to toxicity is observed more often in cancer patients with low 95 
muscle mass, and thus such benefit may be limited [7,13,14].  96 
The development of chemotherapy toxicity may be partially explained by variation in 97 
body composition in patients with cancer [15]. The overall weight is comprised mostly of fat 98 
tissue and non-fat tissue. In turn, non-fat tissue is comprised of bone tissue and lean tissue 99 
such as organ tissues (e.g., liver and kidneys) and muscle tissue [16,17]. Distribution and 100 
metabolism of water soluble chemotherapy agents, such as cisplatin, mainly takes place in the 101 
lean tissue [18]. Therefore, patients with low muscle mass may have a smaller amount of area 102 
available for distribution of chemotherapy agents due the limited amount of lean tissue. 103 
Recent studies have revealed there is considerable variation in the proportions of lean and fat 104 
tissues in patients with cancer, and patients with solid tumors may present as overweight or 105 
obese, while simultaneously showing severe loss of skeletal muscle mass [8,13,19]. Body area 106 
estimates based on body mass and stature are used for dose calculation of chemotherapy 107 
agents such as cisplatin [20]. Thus, if a chemotherapy agent distributes well in lean tissue, 108 
patients with relatively low muscle mass may be at risk of receiving a higher dose of 109 
 
 
chemotherapy agent relative to the actual amount of lean tissue, due to overestimation of lean 110 
tissue. This relatively high dose of chemotherapy may increase risk of chemotherapy toxicity 111 
[7,14,17,21].  112 
Chemotherapy toxicity may result in early termination of chemotherapy [22]. Accurate 113 
identification of patients with low muscle mass is currently possible, since muscle mass has 114 
become identifiable and quantifiable with image-based approaches, such as computed 115 
tomography (CT). CT analysis of the lumbar muscle area has been thoroughly validated for 116 
the evaluation of human body composition and correlates well with lean body mass [23-25]. 117 
In some patient populations, CT images of the lumbar muscle area are not generally available, 118 
and CT analysis of thoracic muscle area may serve as an alternative [26]. However, although 119 
it is now possible to accurately identify patients with low muscle mass, it is still unclear to 120 
what extent toxicity of chemotherapy treatment correlates with muscle area identified with 121 
lumbar or thoracic CT cross-sections in HNC patients. Therefore, we aimed to study whether 122 
low pre-treatment lumbar or thoracic muscle area as measured with CT is associated with 123 
toxicity-related early termination of chemotherapy treatment, in patients with HNC treated 124 
with concomitant radiotherapy and chemotherapy.   125 
 
 
MATERIALS AND METHODS 126 
 127 
Patients and study design 128 
This study was conducted in accordance with the Declaration of Helsinki and approved by the 129 
institutional research ethics board. Data were collected in consecutive adult patients 130 
diagnosed with HNC during their initial visit to the outpatient medical oncology clinic at the 131 
tertiary cancer treatment center serving northern Alberta. Demographic information, and 132 
cancer site and stage were obtained from the Alberta Cancer Registry, certified by the North 133 
American Association for Central Cancer Registries. Cancer stage was based on the American 134 
Joint Committee on Cancer (7th Edition) stage groupings for HNC [27]. HNC tumor sites 135 
were based on the International Classification of Diseases for Oncology (ICD)-O-3 site codes. 136 
Cohorts were sampled from March 2004 until July 2010 (Sample I) and from May 2012 until 137 
May 2016 (Sample II). Adult patients diagnosed with HNC, mainly presenting cancer of the 138 
lip, oral cavity, nose, paranasal sinus, larynx, and pharynx, were considered for inclusion if 139 
they received concomitant radiotherapy and platinum-based chemotherapy treatment (CRT) 140 
with curative intent, with or without prior surgery (Sx). To be considered for inclusion, a 141 
routine diagnostic CT image taken before start of CRT including the 4th thoracic vertebra (T4; 142 
sample I) or the 3th lumbar vertebra (L3; sample II) needed to be available. 143 
The primary treatment for advanced stages of HNC was CRT; in addition, 144 
approximately half of the patients in our cohort had prior HNC surgery, with tumor resection, 145 
bilateral neck dissection, and free flap reconstruction. Radiotherapy treatment included 146 
conventional or tomotherapy 66-76 cGy. The main treatment plans for chemotherapy were 147 
cisplatin 100 mg/m2, three weekly (3 cycles), cisplatin 40 mg/ m2, weekly (7 cycles), or, if 148 
cisplatin could not be tolerated, carboplatin 1.5 area under the curve (AUC) weekly (6-7 149 
cycles). For each patient, chemotherapy type and dose were selected by the treating 150 
 
 
oncologist. If patients had a contraindication to high dose cisplatin such as poor renal function 151 
or pre-existing hearing problems, carboplatin was used in the first instance.  152 
 153 
Measures 154 
Data collected from medical charts included: number of days between CT scan and start of 155 
chemotherapy and radiotherapy; type of treatment; presence of co-morbidities; performance 156 
status was recorded as Eastern Cooperative Oncology Group (ECOG) [28]; alcohol intake; 157 
history of smoking, treatment plan of platinum-based chemotherapy and chemotherapy 158 
toxicities. 159 
 160 
Body composition 161 
Weight and height were recorded according to standard procedures by hospital staff. Weight 162 
(kg) was measured with a medical balance beam scale and height (m) with a stadiometer. 163 
Body mass index (BMI) was calculated [weight (kg)/height (m2)]. Percentage of weight loss 164 
in the last month before starting CRT was retrieved from Patient-Generated Subjective Global 165 
Assessment Short Form data [29], as collected in routine care. Body composition was 166 
assessed by evaluating (PET-)CT images that were taken for diagnostic purposes. Most 167 
studies using this approach have adopted the convention of quantifying muscle cross-sectional 168 
area in a single image landmarked at L3 [22-24,30]. However in HNC routine diagnostic 169 
imaging does not always include the abdominal region, thus we selected T4 as an alternative 170 
vertebral landmark for Sample I, as this region represents large and diverse muscle areas and 171 
was included in staging studies in the majority of patients. For Sample II, routine PET-CT 172 
imaging included L3 in the majority of patients.  173 
 
 
One axial image at T4 or L3 was selected for analysis of total muscle cross-sectional 174 
area (cm2) [23,31]. CT image parameters included: contrast-enhanced, 5 mm slice thickness, 175 
120 kVp, and ~290 mA. Observers were blinded to the patients’ treatment and toxicity status. 176 
Muscles were quantified within a Hounsfield unit range of −29 to +150 HU using Slice-O–177 
Matic software (v.5.0; Tomovision, Magog, Canada). Total muscle cross-sectional area 178 
(SMA) was computed for each image. The directly determined unit for SMA was cm2 of total 179 
T4 or L3 skeletal muscle. Cross-sectional area of total muscle at T4 or L3 were normalized 180 
for stature, and skeletal muscle index (SMI; cm2/m2) was calculated. Correction for deviation 181 
of the mean enables pooling of the SMI results of sample I and sample II, while allowing 182 
continued use of the original unit of measurement (cm2/m2). It could be performed because 183 
standard deviations of T4 and L3 measurements were similar (12.6 cm2/m2 and 10.3 cm2/m2, 184 
respectively). The mean SMI of Sample I was subtracted from all SMI measurements in 185 
Sample I (T4 measurements) and the mean SMI of Sample II was subtracted from all SMI 186 
measurements in Sample II (L3 measurements). After correction for deviation from the mean, 187 
the scores were combined in one pooled SMI variable representing the SMI deviation to the 188 
mean (cm2/m2). 189 
 190 
Outcome measures 191 
In this study, early termination of chemotherapy related to toxicity (‘early termination’) was 192 
considered the primary outcome measure and was defined as completion of at least one cycle 193 
of chemotherapy less than planned. If the initial chemotherapy treatment plan was altered 194 
from cisplatin to carboplatin (often due to ototoxicity), and cycles were completed, this was 195 
not considered an early termination. Otherwise, if early termination was specifically attributed 196 
to toxicity, early termination was considered present. Reduction of the dose of cisplatin or 197 
carboplatin provided all cycles where completed, was not considered early termination. 198 
 
 
Statistical analysis 199 
Mean (standard deviation; SD) or median scores (interquartile range; IQR) are reported for all 200 
continuous variables. Absolute numbers (percentages) are reported for ordinal and 201 
dichotomous variables. Differences between Sample I and Sample II were explored with 202 
Pearson Chi square, Mann-Whitney U test, or independent samples t-test.  203 
  Univariate analysis was used to test the association between pooled SMI and early 204 
termination. Multivariate binary logistic regression analyses were used to investigate possible 205 
effects of sex, age, BMI, presence of co-morbidities (present, not present); ECOG 206 
performance status (ECOG ≤1, ECOG>1), smoking (yes, no), alcohol consumption (yes, no), 207 
tumor site (oropharynx, other), treatment plan (CRT, SxCRT), and type of platin-based 208 
chemotherapy (cisplatin, carboplatin) on early termination. Since multivariate modeling based 209 
on exclusion of variables as a result of their univariate performance (for instance excluding all 210 
variables with a p-value ≥0.10) may result in overlooking possible interactions in the 211 
multivariate analysis, all variables included in the univariate model were also included in the 212 
multivariate analysis, regardless of univariate performance. Due to the large number of  213 
variables, three model selection procedures were explored to identify associations. As a 214 
primary model selection procedure, the penalized regression approach according to the 215 
Smoothly Clipped Absolute Deviation (SCAD) [32] penalty was used, as it performs well in 216 
variable selection without creating bias [33,34].For selecting the explanatory variables, the 217 
value of the penalty parameter is determined by repeating the cross-validation procedure 200 218 
times and taking the mean from these repeats. To test the robustness of the results, the model 219 
resulting from SCAD was compared with that obtained from minimum Akaike Information 220 
Criterion (AIC) [35] and minimizing Bayesian Information Criterion (BIC) [36] approaches. 221 
To allow for analysis of all included patients, missing data were imputed by the Multivariate 222 
 
 
Imputation by Chained Equations procedure for the variables alcohol intake (n=2) and ECOG 223 
performance status (n=13) [37,38].  224 
Furthermore, to provide insight in the relation between SMI, one month weight loss 225 
and early termination, we presented distribution of percentage weight loss in one month 226 
across SMI stratified for early termination being absent or present, and tested for mean 227 
differences with univariate binary logistic regression analysis and for differences in 228 
proportions with Fisher’s exact test. Finally, toxicity profiles of cisplatin-based chemotherapy 229 
treatment may differ from carboplatin-based treatment. Therefore, difference in distribution of 230 
SMI (cm2/m2) stratified for early termination being absent or present was tested for cisplatin 231 
and carboplatin separately with an independent samples Mann-Whitney U test. The 232 
association between muscle mass and early termination was explored with univariate binary 233 
logistic regression, for subgroups treated with cisplatin or carboplatin separately.  234 
In the analyses, a p-level of <0.05 was considered significant and Odds Ratios (OR) 235 
[95% CI] were presented. Descriptive, univariate and explorative analyses were performed 236 
with SPSS (version 24.0 2016, IBM Inc., Chicago, Il). Multivariate analysis was performed 237 






In total, 213 patients met the inclusion criteria and could be included in the analysis (Sample 242 
I: n=93; Sample II: n=120). Characteristics of the included HNC patients prior to CRT are 243 
reported in Table 1. All patients received at least one cycle of chemotherapy. Of these 213 244 
patients, 61 (29%) terminated chemotherapy prematurely. In one patient that terminated 245 
chemotherapy early, the initial chemotherapy treatment plan was altered from cisplatin to 246 
carboplatin. In 28 patients, the initial chemotherapy treatment plan was altered from cisplatin 247 
to carboplatin, and treatment was considered completed. The following reasons for early 248 
termination of chemotherapy treatment were not considered toxicity-related: non-completion 249 
due to non-compliance (n=4); further chemotherapy treatment not indicated (n=2); non-250 
completion of CRT due to reported radiation-related side effects (n=2); postponement of 251 
treatment due to surgical infections (n=1) or personal circumstances (n=1). Dose reduction of 252 
chemotherapy treatment ranged from 25% to 90% and occurred in 19 patients. Seven of these 253 
patients had toxicity-related dose reductions preceding early termination, and early 254 
termination was considered present. In eight patients the reason for dose reduction was not 255 
described and all cycles were completed, and early termination was not considered present. 256 
Finally, in four patients dose reductions were related to chemotherapy toxicity, but all cycles 257 
were completed, and early termination was not considered present.  258 
 259 
Body composition measurements 260 
In Sample I, CT images at T4 level of 93 eligible patients were analyzed. In sample II, CT 261 
images at L3 level were available in 120 of 124 (94.4%) eligible HNC patients. All selected 262 
images could be analyzed and SMI was calculated. Pre-treatment anthropometrical 263 
measurements and indices of body composition of the participants are presented in Table 2. 264 
 
 
Patients that altered their treatment from cisplatin to carboplatin did not have a significantly 265 
different pooled SMI when compared to patients continuously treated with cisplatin 266 
(p=0.823), or when compared to all other patients (p=0.541). Frequency of early termination 267 
did not significantly differ between patients treated with cisplatin 100 mg/m2 and cisplatin 40 268 
mg/m2 (p=0.864). The univariate and multivariate modeling analysis of pooled SMI and early 269 
termination corrected for possible confounding variables in HNC patients is presented in 270 
Table 3. In addition to pooled SMI, variables that emerged associated with early termination 271 
were sex, type of chemotherapy, co-morbidity and (former) smoking combined with alcohol 272 
consumption. The time interval between CT and CRT was significantly different for Sample I 273 
and Sample II (p<0.001). To rule out possible effect modification, the time interval between 274 
CT and CRT (days) was therefore added to the statistical modeling analyses. However, time 275 
interval between CT and CRT was not identified as effect modifier of pooled SMI on early 276 
termination in the AIC, BIC, or SCAT model. Associated odds of early termination of 277 
chemotherapy treatment across the distribution of pooled SMI in HNC patients are presented 278 
in Figure 1.  279 
Percentage one month weight loss was significantly associated with early termination 280 
(p<0.001). Additionally, interaction between SMI and early termination appeared different 281 
depending on the level of one month weight loss and vice versa, indicating SMI and one 282 
month weight loss may modify each other’s effects on early termination. Since the focus was 283 
on the association between SMI and early termination, weight loss was not included in the 284 
primary analysis. Instead, the association between SMI and percentage one month weight loss 285 
across SMI stratified for early termination is presented separately in Figure 2.  286 
Figure 3 illustrates the distribution of SMI stratified by absence or presence of early 287 
termination of chemotherapy for cisplatin-based and carboplatin-based treatment in patients 288 
with head and neck cancer. To further explore the association between muscle mass and early 289 
 
 
termination for the different types of chemotherapy agents, a sub-analysis was performed for 290 
the cisplatin and the carboplatin subgroup, respectively. The sub-analysis showed that in the 291 
cisplatin subgroup, a higher SMI was significantly associated with a lower incidence of early 292 
termination (p=0.025; OR 0.96 [95% CI: 0.93-1.00]). This indicates that if SMI is 1 cm2/m2 293 
higher, the odds of early termination decrease with 4% in the patients treated with cisplatin. 294 
Also in the carboplatin subgroup, a higher SMI was significantly associated with a lower 295 
incidence of early termination (p=0.041; OR 0.93 [95% CI: 0.86-1.00]). This indicates that if 296 
SMI is 1 cm2/m2 higher, the odds of early termination decrease with 7% in the patients treated 297 
with carboplatin. 298 





The results of our study indicate that cross-sectional measurements of large and representative 302 
muscle areas are significantly associated with incidence of toxicity-related early termination 303 
of chemotherapy in patients with HNC. A lower level of lumbar and thoracic SMI of 1 304 
cm2/m2 was firmly associated with 4 to 5% higher odds of early termination of chemotherapy. 305 
Conversely, a higher level of lumbar and thoracic SMI of 1 cm2/m2 was firmly associated 306 
with 4 to 5% lower odds of early termination of chemotherapy. In our population, one month 307 
weight loss was significantly associated with early termination and modified the effect of 308 
SMI, and vice versa. Patients with SMI below mean and weight loss showed significantly 309 
higher changes of early termination of treatment. Co-variables that were selected in one or 310 
more models of the multivariate analysis were type of chemotherapy, presence of co-311 
morbidity, alcohol consumption, smoking, combined alcohol consumption and smoking, and 312 
sex. Of these variables, type of chemotherapy, presence of co-morbidity, and combined 313 
alcohol consumption and smoking were significantly associated with early termination in one 314 
or more models of the multivariate analysis.  315 
The results of this study agree with other studies that have shown that cancer patients 316 
with low muscle mass generally are vulnerable to chemotherapy toxicity [6,15,21,39]. We 317 
speculate that this could be partially explained by higher concentrations of water soluble 318 
chemotherapy agents such as cisplatin and, to a lesser extent, carboplatin in lean tissues in 319 
patients with low muscle mass [18]. Our exploratory results also indicate that for both 320 
cisplatin-based and carboplatin-based chemotherapy, lower muscle mass was associated with 321 
a significantly higher incidence of early termination. Alternatively, complications of 322 
chemotherapy may also be explained by reduced overall function as a result of low muscle 323 
mass. Studies show that cancer patients with low muscle mass are also vulnerable to a range 324 
 
 
of other problems, such as slower recovery, complications from surgery, and shorter survival 325 
[5,40-42].  326 
Availability of abdominal CT images was better than reported in other studies in HNC 327 
patients [43, 44]. Whereas in Sample I (2004-2010), diagnostic CT images of head and chest 328 
were standard practice in head and neck cancer patients, in Sample II (2012-2016), a 94% 329 
availability of L3 level CT measurements was encountered. This broad availability of 330 
abdominal CT images can be explained by the implementation of routine imaging with whole 331 
body PET-CT scans in the more recent Sample II. Although in recent years a growing number 332 
of HNC patients have whole body PET-CT scans for staging purposes, routine abdominal 333 
imaging is currently not part of NCCN guidelines, and clinical practice varies per country and 334 
institution [32]. As long as not all CT cross-sectional areas are as well-validated as L3, before 335 
deciding on analyzing thoracic or cervical muscle areas in HNC patients, we recommend to 336 
first explore the availability of whole body PET-CT scans, and thus L3 images.  337 
To our knowledge, our study is the first to include CT cross-sections of large and 338 
representative lumbar and thoracic muscle areas in head and neck cancer patients. The results 339 
of our advanced statistical analysis confirmed the results of a study that explored the 340 
association between CT cross-sections of smaller cervical muscle areas and toxicity-related 341 
early termination in HNC patients [44]. Additionally, our study identified possible 342 
interactions of SMI and early termination with type of chemotherapy regimen,  presence of 343 
co-morbidity, and combined smoking and alcohol consumption.  344 
Our study also had some limitations. Firstly, we were not able to acquire CT images 345 
that included cross-sections of L3 vertebra for all patients. Currently, a validated formula is 346 
available for cross-sectional muscle area at L3 level, [25] but not for T4 level. Therefore, lean 347 
body mass on the whole body level could not be estimated. However, we were able to pool 348 
 
 
and interpret results by correcting T4 and L3 measurements for deviation to their means. 349 
Secondly, type and dose of chemotherapy were significantly different between Sample I 350 
(2004-2010) and Sample II (2012-2016). This difference resulted from adaptations in head 351 
and neck cancer treatment guidelines, in which use of carboplatin is nowadays less often 352 
recommended and use of the lower dose of cisplatin is more often recommended. As a result, 353 
the subgroup of patients treated with weekly cisplatin (40 mg/m2) in our sample was limited 354 
(n=34). However, toxicity-related early termination did not significantly differ between the 355 
subgroup of patients treated with high dose cisplatin 100 mg/m2 and those treated with weekly 356 
cisplatin 40 mg/m2. Also, studies indicate that high-dose cisplatin at 100 mg/m2 and weekly 357 
cisplatin at 40 mg/m2 have similar cumulative dose and toxicity profiles [45-47]. Hence, we 358 
considered it justified to dichotomize type of chemotherapy treatment into cisplatin versus 359 
carboplatin in the multivariate analysis. Finally, we combined the data of patients with CRT 360 
and surgery prior to CRT. Patients with surgery prior to CRT may have a different disease 361 
profile than patients that did not have surgery prior to CRT [12]. Therefore, we included 362 
presence or absence of surgery as a co-variable in our statistical analysis. This statistical 363 
analysis showed no significant difference in early termination of treatment for both groups.  364 
 Chemotherapy (e.g. cisplatin) has important radiosensitizing capacities and patients 365 
with HNC treated with concomitant chemotherapy and radiotherapy have high survival [48]. 366 
For cisplatin dose, response studies suggest that a cumulative dose of >200 mg/m2 is needed 367 
for survival benefit of chemotherapy [46,47]. This will not be achieved if treatment is 368 
terminated early. Since incidence of early termination is higher in patients with lower muscle 369 
mass, the odds of treatment completion may improve if patients receive chemotherapy 370 
treatment that is tailored to their muscle mass or lean body mass instead of whole body area 371 
estimates. Further prospective studies are required to develop a dosing strategy that will be 372 
tolerated by patients with lower muscle mass and avoid early termination. Also, adjusting 373 
 
 
chemotherapy dosage to prevent toxicity should not be considered without testing possible 374 
effects of adjustments on disease control.  375 
Additionally, our study was a retrospective study, and thus some covariables could not 376 
be studied in great detail. Therefore, in future studies on muscle mass and chemotherapy 377 
toxicity in patients with HNC, we recommend taking into account more in-depth analyses of 378 
covariables such as weight loss, type of chemotherapy, presence of co-morbidity, and 379 
combined smoking and alcohol consumption and sex. These variables may possibly interact 380 
with chemotherapy toxicity. For instance, the relationship between low muscle mass and 381 
weight loss combined and early termination of chemotherapy treatment needs further study. 382 
Further, presence of co-morbidity could be explored with more attention for severity of co-383 
morbidities (for instance by implementing the Charlson co-morbidity index). Finally, the 384 
association between (combined) drinking and smoking and SMI needs further exploration, 385 
and the association between combined drinking and smoking and early termination of 386 
chemotherapy treatment could be further explored by stratifying for quantities of alcohol 387 
intake and smoking. 388 
In conclusion, in this study we found that a lower muscle mass is associated with 389 
higher odds of toxicity-related early termination of chemotherapy treatment in patients with 390 
HNC. Further prospective studies are required to tailor the care for patients with low muscle 391 
mass and to avoid early termination of chemotherapy. 392 
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Legends to Figures 566 
Figure 1. Associated odds of early termination of chemotherapy treatment for skeletal muscle 567 
index (SMI; cm2/m2) in patients with head and neck cancer. 568 
Figure 2. Distribution of 1 month weight loss percentage across absence (cross) or presence 569 
(circle) for early termination of chemotherapy for skeletal muscle index corrected for 570 
deviation of the mean (SMI: cm2/m2) in patients with head and neck cancer. 571 
Figure 3. Distribution of skeletal muscle index corrected for deviation of the mean  572 
(SMI: cm2/m2) across absence (left) or presence (right) of early termination of chemotherapy 573 
for cisplatin-based and carboplatin-based treatment in patients with head and neck cancer.  574 
Table 1. Characteristics of patients with head and neck cancer prior to chemo-radiotherapy 









(Mean) diff  
p value 
Age ( years) 




















 Oral cavity 
 Pharynx 
 Larynx 






































































Mode of treatment 
Primary chemo-radiotherapy (CRT) 














Time between CT and CRT (days)  












Type and dose of chemotherapy 
- Cisplatin 100 mg/m2 
- Cisplatin 40 mg/m2 















ECOG performance status (%) 
0. Normal 
1. Not normal self 
2. Not feeling up to most 
3. Little activity 



































Significance set at a 0.05 level 
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Early termination of 














Significance set at a 0.05 level 
Table 2. Anthropometrics and indices of body composition of head and neck cancer patients 
prior to chemo-radiotherapy treatment  




Sample Ia  
N=93 
Sample IIb  
N=120 
(mean) diff 
Sample I and 
II, p-value 
Body weight Mean ± SD 
Overall kg 
Male kg 
Female  kg 


















Weight loss in 1 monthc  Mean ± SD 
Overall % 
Male % 
Female  % 












































(mean) difference male and female, p-value 
 
































*Significance set at a 0.05 level 
a Sample I: 4th thoracic vertebra (T4) as vertebral landmark. 
b Sample II: 3th lumbar vertebra (L3) as vertebral landmark.  
c Percentage of weight loss in one month reported at intake for chemo-radiotherapy.  
 
Table 2
Table 3. Univariate and multivariate modeling analysis of skeletal muscle index and toxicity-related early termination of chemotherapy treatment corrected for 




Early termination of chemotherapy related to toxicity 
Univariate (n=213) Multivariate (n=213) 
OR [95%Cl] p-value AIC OR [95% CI] p-value BIC OR [95%Cl] p-value SCAD OR [95%] p-value 
Skeletal muscle index (cm2/m2)a 0.96 [0.94-0.99] 0.007b 0.95 [0.92-0.98] 0.001b 0.96 [0.93-0.99] 0.004b 0.96 [0.92-0.99] 0.021b 
Body mass index (BMI; kg/m2) 0.97 [0.92-1.03] 0.277       

















      
































Time between CT and CRT (days) 1.00 [0.99-1.01] 0.598       
a Pooled T4 and L3 skeletal muscle index corrected for deviation from the mean; b Significance set at a 0.05 level 
  
Table 3




Early termination of chemotherapy related to toxicity 
Univariate (n=213) Multivariate 
OR [95%Cl] p-value AIC OR [95% CI] p-value BIC OR [95%Cl] p-value SCAT OR [95%] p-value 






   
 
   







































    


















Magnitude of toxicity related unplanned early termination 
of chemotherapy is assessed with SCAD analysis of 
skeletal muscle index (SMI; cm2/m2). Positive deviation 
from the group mean is associated with decrease of the 
odds of early termination: an SMI that is 1 cm2/m2 higher 
indicates a decrease in odds of early termination of 4% 
(OR=0.96). An SMI that is 20 cm2/m2 higher indicates a 
decrease in odds of early termination of 57%  (OR=0.43). 
Accordingly, negative deviation from the group mean is 
associated with an increase of the odds for early 
termination: an SMI that is 1 cm2/m2 lower indicates an 
increase of odds of early termination of 4% (OR=1.04). 
An SMI that is 20 cm2/m2 lower indicates an increase of 
odds of early termination of 134% (OR=2.34). 
 
SMI deviation 
to the mean 
(cm2/m2) 
Corresponding 
lumbar or thoracic 
SMI (cm2/m2) 




 lumbar thoracic  
+20 71.6 85.5 0.43 (0.20-0.86) 
+10 61.6 75.5 0.65 (0.45-0.93) 
+1 52.6 66.5 0.96 (0.92-0.99) 
0  51.6 65.5 1.00 
-1 50.6 64.5 1.04 (1.01-1.08) 
-10 41.6 55.5 1.53 (1.08-2.21) 
-20 31.6 45.5 2.34 (1.16-4.90) 




















































*n patients with early termination present; p-values calculated with Fisher’s exact test; 
**significance assumed at p<0.05 
Figure 2
 
Figure 2. Distribution of 1 month weight loss percentage across absence (cross) or presence (circle) for early termination of chemotherapy 





* Number (%) of patients with early termination absent or present.  
** Difference in distribution of SMI (cm2/m2) across early termination absent or present for cisplatin and carboplatin was tested with an 

































Figure 3. Distribution of skeletal muscle index corrected for deviation from the mean (SMI: cm2/m2) across absence (left) or presence (right) of early 
termination of chemotherapy for cisplatin-based and carboplatin-based treatment in patients with head and neck cancer.  
 
